Nxera Joins OpenFold AI Research Consortium to Strengthen Drug Discovery Capabilities
Wednesday, June 10, 2026
Nxera Pharma has joined OpenFold, a non-profit artificial intelligence research consortium focused on developing open-source AI tools for biology and drug discovery.
The consortium brings together a global network of pharmaceutical, biotechnology, technology and academic organisations. Supporting members include major technology companies such as Amazon Web Services, Microsoft and NVIDIA. Other participants include Bristol Myers Squibb, Novo Nordisk, Bayer and Roche.
OpenFold operates as a project of the Open Molecular Software Foundation and works with academic partners such as Columbia University. The consortium develops open-source structural prediction models and tools, including OpenFold, OpenFold-Multimer and OpenFold3-preview.
Nxera said its participation supports the company’s strategy of improving research and development productivity through the use of AI technologies. The company’s proprietary NxWave™ platform combines expertise in GPCR structure-based drug discovery, proprietary datasets, computational chemistry and AI-driven technologies to support drug discovery programmes.
Through its involvement in OpenFold, Nxera plans to evaluate and apply advanced open-source structural prediction models, conduct performance benchmarking for GPCR targets, contribute to future research discussions within the consortium and strengthen its AI-enabled computational chemistry capabilities.
The company will participate as a user of the consortium’s open-source tools and will not be required to provide proprietary data or intellectual property.
Nxera believes that access to OpenFold’s collaborative ecosystem will help enhance its AI-driven drug discovery efforts, particularly in the development of therapies targeting G protein-coupled receptors (GPCRs), an important but challenging class of drug targets. The initiative also supports the company’s broader objective of increasing research and development efficiency as part of its long-term growth strategy.
Source: eir-parts.net
